# SERPINB13

## Overview
SERPINB13 is a gene that encodes the protein serpin family B member 13, which is part of the serine protease inhibitor (serpin) family. This protein functions primarily as an intracellular inhibitor of serine proteases, playing a vital role in regulating protease activity within various epithelial tissues and certain neuroendocrine cells (de2009Downregulation). The protein is particularly significant in maintaining cellular and tissue integrity by preventing protease-mediated damage, which is crucial for processes such as inflammation and wound healing. In pancreatic islets, SERPINB13 is involved in regulating cellular proliferation, influencing beta cell renewal and potentially impacting conditions like diabetes (Lo2019Cellular; Kryvalap2016Antibody). Additionally, alterations in SERPINB13 expression have been linked to clinical outcomes in head and neck squamous cell carcinomas, highlighting its importance in both normal physiological processes and disease states (de2009Downregulation).

## Function
SERPINB13, a member of the serpin family, functions as an intracellular serine protease inhibitor, playing a crucial role in regulating protease activity within cells. It is primarily expressed in epithelial tissues, including keratinizing and nonkeratinizing squamous epithelium, respiratory epithelium, and transitional epithelium, as well as in a subset of neuroendocrine cells in the pituitary gland (de2009Downregulation). This protein is involved in maintaining cellular and tissue integrity by protecting cells from protease-mediated damage, which is essential for processes such as inflammation and wound healing.

In the context of pancreatic islets, SERPINB13 is implicated in regulating cellular proliferation. Its inhibition has been shown to enhance beta cell proliferation through the upregulation of REG genes, which are associated with islet cell development and renewal (Lo2019Cellular). This process is mediated by increased cathepsin L protease activity, which is necessary for the observed effects on beta cell proliferation (Lo2019Cellular). The interaction between exocrine and endocrine pancreatic tissues, facilitated by SERPINB13, contributes to beta cell renewal, highlighting its role in maintaining pancreatic function and potentially influencing conditions like diabetes (Kryvalap2016Antibody).

## Clinical Significance
Alterations in the expression of the SERPINB13 gene have been linked to various clinical outcomes, particularly in head and neck squamous cell carcinomas (HNSCC). Downregulation of SERPINB13 is associated with poor tumor differentiation, lymph node metastasis, and decreased survival rates in HNSCC patients. This downregulation is observed in 75% of HNSCC cases and correlates with adverse clinical features, such as increased risk of death and recurrent disease (de2009Downregulation). The loss of heterozygosity (LOH) at chromosome 18q21.3, where SERPINB13 is located, is significantly associated with its downregulation, suggesting a potential genetic mechanism underlying these clinical outcomes (de2009Downregulation).

In the context of type 1 diabetes mellitus, the presence of antibodies against SERPINB13 has been linked to adaptive changes in pancreatic islets, potentially slowing the decline in beta cell function. This antibody response is associated with increased beta cell proliferation and improved blood glucose levels in experimental models, indicating a protective role against diabetes-related metabolic stress (Kryvalap2016Antibody). These findings suggest that SERPINB13 may play a role in regulating pancreatic islet function and could have therapeutic implications for diabetes management (Lo2019Cellular; Kryvalap2016Antibody).

## Interactions
SERPINB13, a member of the serpin family, is known to interact with cysteine proteases, particularly cathepsin L (CatL). This interaction is significant in the regulation of cellular proliferation in pancreatic islets. SERPINB13 acts as an inhibitor of CatL, and its inhibition leads to increased CatL activity. This increased activity results in the cleavage of E-cadherin, a process that promotes the upregulation of REG genes and enhances beta cell proliferation in pancreatic islets (Lo2019Cellular).

The interaction between SERPINB13 and CatL is part of a pathway that involves the modulation of E-cadherin and β-catenin signaling. When SERPINB13 is inhibited, CatL activity increases, leading to decreased E-cadherin levels. This reduction in E-cadherin allows for increased β-catenin signaling, which further supports the expression of REG genes and beta cell proliferation (Lo2019Cellular).

SERPINB13 can also be exposed to the extracellular environment under certain conditions, such as tissue damage, allowing it to modulate protease activity outside the cell. This extracellular presence is crucial for maintaining the balance between proteases and antiproteases, particularly in pancreatic islets (Kryvalap2022The).


## References


[1. (Lo2019Cellular) Chi-Wen Lo, Yury Kryvalap, Tzong-jen Sheu, Ching-Ho Chang, and Jan Czyzyk. Cellular proliferation in mouse and human pancreatic islets is regulated by serpin b13 inhibition and downstream targeting of e-cadherin by cathepsin l. Diabetologia, 62(5):822–834, March 2019. URL: http://dx.doi.org/10.1007/s00125-019-4834-0, doi:10.1007/s00125-019-4834-0. This article has 4 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-019-4834-0)

[2. (de2009Downregulation) Pieter J.A. de Koning, Niels Bovenschen, Frank K.J. Leusink, Roel Broekhuizen, Razi Quadir, Jan T.M. van Gemert, Gerrit J. Hordijk, Wun‐Shaing W. Chang, Ingeborg van der Tweel, Marcel G.J. Tilanus, and J. Alain Kummer. Downregulation of serpinb13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome. International Journal of Cancer, 125(7):1542–1550, June 2009. URL: http://dx.doi.org/10.1002/ijc.24507, doi:10.1002/ijc.24507. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.24507)

[3. (Kryvalap2016Antibody) Yury Kryvalap, Chi-Wen Lo, Ekaterina Manuylova, Raman Baldzizhar, Nicholas Jospe, and Jan Czyzyk. Antibody response to serpin b13 induces adaptive changes in mouse pancreatic islets and slows down the decline in the residual beta cell function in children with recent onset of type 1 diabetes mellitus. Journal of Biological Chemistry, 291(1):266–278, January 2016. URL: http://dx.doi.org/10.1074/jbc.M115.687848, doi:10.1074/jbc.m115.687848. This article has 9 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M115.687848)

[4. (Kryvalap2022The) Yury Kryvalap and Jan Czyzyk. The role of proteases and serpin protease inhibitors in β-cell biology and diabetes. Biomolecules, 12(1):67, January 2022. URL: http://dx.doi.org/10.3390/biom12010067, doi:10.3390/biom12010067. This article has 12 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom12010067)